Which has stronger earnings & valuation, TRAX or XENE?

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A Xenon Pharmaceuticals N/A N/A -$345.91M -$4.74 N/A

Is TRAX or XENE more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A Xenon Pharmaceuticals N/A -43.98% -41.72%

Does the media prefer LGND or TRAX?

In the previous week, First Tracks Biotherapeutics had 9 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 11 mentions for First Tracks Biotherapeutics and 2 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.90 beat First Tracks Biotherapeutics' score of 0.14 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive First Tracks Biotherapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, ERAS or TRAX?

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.95 N/A First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A

Is ERAS or TRAX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -38.43% -32.05% First Tracks Biotherapeutics N/A N/A N/A

Does the media refer more to ERAS or TRAX?

In the previous week, First Tracks Biotherapeutics had 1 more articles in the media than Erasca. MarketBeat recorded 11 mentions for First Tracks Biotherapeutics and 10 mentions for Erasca. Erasca's average media sentiment score of 1.23 beat First Tracks Biotherapeutics' score of 0.14 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive First Tracks Biotherapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TRAX or CRSP?

In the previous week, CRISPR Therapeutics had 2 more articles in the media than First Tracks Biotherapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 11 mentions for First Tracks Biotherapeutics. CRISPR Therapeutics' average media sentiment score of 0.36 beat First Tracks Biotherapeutics' score of 0.14 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment First Tracks Biotherapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

First Tracks Biotherapeutics (TRAX) Competitors

$40.46 -2.05 (-4.82%)

As of 09/4/2026 04:00 PM Eastern

Compare

TRAX vs. XENE, LGND, ERAS, CRSP, and GRFS

Should you buy First Tracks Biotherapeutics stock or one of its competitors? First Tracks Biotherapeutics's main competitors and comparable companies include Xenon Pharmaceuticals (XENE), Ligand Pharmaceuticals (LGND), Erasca (ERAS), CRISPR Therapeutics (CRSP), and Grifols (GRFS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does First Tracks Biotherapeutics compare to Xenon Pharmaceuticals?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

95.4% of Xenon Pharmaceuticals shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

First Tracks Biotherapeutics presently has a consensus price target of $63.00, indicating a potential upside of 55.71%. Xenon Pharmaceuticals has a consensus price target of $77.13, indicating a potential upside of 29.09%. Given First Tracks Biotherapeutics' higher probable upside, analysts plainly believe First Tracks Biotherapeutics is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Xenon Pharmaceuticals had 4 more articles in the media than First Tracks Biotherapeutics. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 11 mentions for First Tracks Biotherapeutics. Xenon Pharmaceuticals' average media sentiment score of 1.27 beat First Tracks Biotherapeutics' score of 0.14 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
First Tracks Biotherapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
Xenon Pharmaceuticals	N/A	N/A	-$345.91M	-$4.74	N/A

First Tracks Biotherapeutics' return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

Summary

Xenon Pharmaceuticals beats First Tracks Biotherapeutics on 8 of the 12 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Ligand Pharmaceuticals has higher revenue and earnings than First Tracks Biotherapeutics. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	21.24	$124.45M	$9.35	30.55
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

In the previous week, First Tracks Biotherapeutics had 9 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 11 mentions for First Tracks Biotherapeutics and 2 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.90 beat First Tracks Biotherapeutics' score of 0.14 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
First Tracks Biotherapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ligand Pharmaceuticals has a net margin of 67.88% compared to First Tracks Biotherapeutics' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 20.06% beat First Tracks Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
First Tracks Biotherapeutics	N/A	N/A	N/A

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ligand Pharmaceuticals currently has a consensus price target of $335.75, suggesting a potential upside of 17.56%. First Tracks Biotherapeutics has a consensus price target of $63.00, suggesting a potential upside of 55.71%. Given First Tracks Biotherapeutics' higher possible upside, analysts plainly believe First Tracks Biotherapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Ligand Pharmaceuticals beats First Tracks Biotherapeutics on 10 of the 12 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Erasca?

Erasca (NASDAQ:ERAS) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

First Tracks Biotherapeutics' return on equity of 0.00% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-38.43%	-32.05%
First Tracks Biotherapeutics	N/A	N/A	N/A

Erasca presently has a consensus target price of $22.09, indicating a potential upside of 36.45%. First Tracks Biotherapeutics has a consensus target price of $63.00, indicating a potential upside of 55.71%. Given First Tracks Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe First Tracks Biotherapeutics is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, First Tracks Biotherapeutics had 1 more articles in the media than Erasca. MarketBeat recorded 11 mentions for First Tracks Biotherapeutics and 10 mentions for Erasca. Erasca's average media sentiment score of 1.23 beat First Tracks Biotherapeutics' score of 0.14 indicating that Erasca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
First Tracks Biotherapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

67.8% of Erasca shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

First Tracks Biotherapeutics beats Erasca on 6 of the 11 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to CRISPR Therapeutics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

In the previous week, CRISPR Therapeutics had 2 more articles in the media than First Tracks Biotherapeutics. MarketBeat recorded 13 mentions for CRISPR Therapeutics and 11 mentions for First Tracks Biotherapeutics. CRISPR Therapeutics' average media sentiment score of 0.36 beat First Tracks Biotherapeutics' score of 0.14 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
First Tracks Biotherapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

69.2% of CRISPR Therapeutics shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

First Tracks Biotherapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. First Tracks Biotherapeutics' return on equity of 0.00% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

First Tracks Biotherapeutics presently has a consensus price target of $63.00, indicating a potential upside of 55.71%. CRISPR Therapeutics has a consensus price target of $68.06, indicating a potential upside of 21.99%. Given First Tracks Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe First Tracks Biotherapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61

First Tracks Biotherapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
CRISPR Therapeutics	$11M	490.41	-$581.60M	-$4.76	N/A

Summary

CRISPR Therapeutics beats First Tracks Biotherapeutics on 8 of the 14 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Grifols?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Grifols (NASDAQ:GRFS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Grifols has higher revenue and earnings than First Tracks Biotherapeutics. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
Grifols	$8.51B	0.62	$454.82M	$0.19	41.05

First Tracks Biotherapeutics currently has a consensus target price of $63.00, suggesting a potential upside of 55.71%. Grifols has a consensus target price of $10.00, suggesting a potential upside of 28.21%. Given First Tracks Biotherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe First Tracks Biotherapeutics is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, First Tracks Biotherapeutics had 11 more articles in the media than Grifols. MarketBeat recorded 11 mentions for First Tracks Biotherapeutics and 0 mentions for Grifols. First Tracks Biotherapeutics' average media sentiment score of 0.14 beat Grifols' score of 0.00 indicating that First Tracks Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
First Tracks Biotherapeutics	Neutral
Grifols	Neutral

Grifols has a net margin of 5.54% compared to First Tracks Biotherapeutics' net margin of 0.00%. Grifols' return on equity of 6.21% beat First Tracks Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Grifols	5.54%	6.21%	2.39%

Summary

Grifols beats First Tracks Biotherapeutics on 6 of the 11 factors compared between the two stocks.

Get First Tracks Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRAX vs. The Competition

Export

Metric	First Tracks Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.52B	$4.02B	$7.28B	$12.92B
Dividend Yield	N/A	3.60%	2.53%	8.90%
P/E Ratio	-21.99	12.65	272.43	25.42
Price / Sales	N/A	1,369.11	634.35	95.42
Price / Cash	N/A	107.40	77.39	52.28
Price / Book	8.57	16.15	12.85	6.17
Net Income	N/A	-$22.76M	$3.48B	$349.50M
7 Day Performance	-3.34%	0.30%	0.99%	-0.15%
1 Month Performance	-13.82%	8.24%	5.49%	1.02%
1 Year Performance	N/A	49.08%	24.34%	14.50%

First Tracks Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRAX First Tracks Biotherapeutics	2.9981 of 5 stars	$40.46 -4.8%	$63.00 +55.7%	N/A	$1.52B	N/A	N/A	N/A	News Coverage Analyst Forecast Insider Trade Gap Down
XENE Xenon Pharmaceuticals	2.5434 of 5 stars	$59.64 -1.3%	$77.13 +29.3%	+54.6%	$5.77B	$7.50M	N/A	210	Positive News Insider Trade
LGND Ligand Pharmaceuticals	3.9043 of 5 stars	$287.48 -0.8%	$335.75 +16.8%	+70.3%	$5.73B	$268.09M	30.75	80
ERAS Erasca	2.3474 of 5 stars	$16.04 -1.4%	$22.09 +37.7%	+993.9%	$5.62B	N/A	N/A	120	Positive News
CRSP CRISPR Therapeutics	2.5282 of 5 stars	$55.75 -1.3%	$68.06 +22.1%	+5.8%	$5.39B	$3.51M	N/A	460

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRAX) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

First Tracks Biotherapeutics (TRAX) Competitors

TRAX vs. XENE, LGND, ERAS, CRSP, and GRFS

How does First Tracks Biotherapeutics compare to Xenon Pharmaceuticals?

Summary

How does First Tracks Biotherapeutics compare to Ligand Pharmaceuticals?

Summary

How does First Tracks Biotherapeutics compare to Erasca?

Summary

How does First Tracks Biotherapeutics compare to CRISPR Therapeutics?

Summary

How does First Tracks Biotherapeutics compare to Grifols?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAX vs. The Competition

First Tracks Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

First Tracks Biotherapeutics (TRAX) Competitors

TRAX vs. XENE, LGND, ERAS, CRSP, and GRFS

How does First Tracks Biotherapeutics compare to Xenon Pharmaceuticals?

Do institutionals & insiders believe in TRAX or XENE?

Do analysts prefer TRAX or XENE?

Does the media favor TRAX or XENE?

Which has stronger earnings & valuation, TRAX or XENE?

Is TRAX or XENE more profitable?

Summary

How does First Tracks Biotherapeutics compare to Ligand Pharmaceuticals?

Which has preferable earnings and valuation, LGND or TRAX?

Does the media prefer LGND or TRAX?

Is LGND or TRAX more profitable?

Do institutionals and insiders have more ownership in LGND or TRAX?

Do analysts rate LGND or TRAX?

Summary

How does First Tracks Biotherapeutics compare to Erasca?

Is ERAS or TRAX more profitable?

Do analysts rate ERAS or TRAX?

Does the media refer more to ERAS or TRAX?

Which has preferable earnings and valuation, ERAS or TRAX?

Do institutionals & insiders believe in ERAS or TRAX?

Summary

How does First Tracks Biotherapeutics compare to CRISPR Therapeutics?

Does the media prefer TRAX or CRSP?

Do institutionals and insiders hold more shares of TRAX or CRSP?

Is TRAX or CRSP more profitable?

Do analysts recommend TRAX or CRSP?

Which has higher valuation and earnings, TRAX or CRSP?

Summary

How does First Tracks Biotherapeutics compare to Grifols?

Which has stronger earnings and valuation, TRAX or GRFS?

Do analysts prefer TRAX or GRFS?

Does the media refer more to TRAX or GRFS?

Is TRAX or GRFS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAX vs. The Competition

First Tracks Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools